Untch M, Jackisch C, Schneeweiss A, et al. – Given that the GeparSepto trial demonstrated significant improvement in the pathologic complete remission rate in correlation with weekly nanoparticle albumin-bound (NAB)–paclitaxel vs weekly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients with primary breast cancer (BC), researchers reported on long-term outcomes. Treatment was initiated in a total of 1,206 patients, of whom 606 received NAB-paclitaxel and 600 received sb-paclitaxel. Observations revealed that the significantly higher pathologic complete response rate in patients with early BC receiving NAB-paclitaxel translate to a significantly improved invasive disease-free survival as compared with those receiving sb-paclitaxel. Overall, NAB-paclitaxel 125 mg/m² compared with NAB-paclitaxel 150 mg/m² led to much faster improvement in peripheral sensory neuropathy.